Evidence map›Paper›PMID 36333414›Full record

ArticleScientific reports2022

iPSC-neural crest derived cells embedded in 3D printable bio-ink promote cranial bone defect repair.

Juliane D Glaeser, Xianchao Bao, Giselle Kaneda, Pablo Avalos, Phillip Behrens, Khosrowdad Salehi, Xiaoyu Da, Angel Chen, Chloe Castaneda, Pawel Nakielski and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. iPSC-derived tenocytes seeded on microgrooved 3D printed scaffolds for Achilles tendon regeneration.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2023
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Juliane D Glaeser *Orthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, 127 S San Vicente Blvd. AHSP A8308, Los Angeles, CA, 90048, USA.
Xianchao Bao *Orthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, 127 S San Vicente Blvd. AHSP A8308, Los Angeles, CA, 90048, USA.
Giselle KanedaOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, 127 S San Vicente Blvd. AHSP A8308, Los Angeles, CA, 90048, USA.
Pablo AvalosBoard of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, 127 S San Vicente Blvd. AHSP A8308, Los Angeles, CA, 90048, USA.
Phillip BehrensOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, 127 S San Vicente Blvd. AHSP A8308, Los Angeles, CA, 90048, USA.
Khosrowdad SalehiOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, 127 S San Vicente Blvd. AHSP A8308, Los Angeles, CA, 90048, USA.
Xiaoyu DaCedars-Sinai Medical Center, Biomedical Imaging Research Institute, 116 N Robertson Blvs. Pacific Theatres Building, Suite 400, Los Angeles, CA, 90048, USA.
Angel ChenOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, 127 S San Vicente Blvd. AHSP A8308, Los Angeles, CA, 90048, USA.
Chloe CastanedaOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, 127 S San Vicente Blvd. AHSP A8308, Los Angeles, CA, 90048, USA.
Pawel NakielskiOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, 127 S San Vicente Blvd. AHSP A8308, Los Angeles, CA, 90048, USA.
Wensen JiangOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, 127 S San Vicente Blvd. AHSP A8308, Los Angeles, CA, 90048, USA.
Wafa TawackoliOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, 127 S San Vicente Blvd. AHSP A8308, Los Angeles, CA, 90048, USA.
Dmitriy SheynOrthopaedic Stem Cell Research Laboratory, Cedars-Sinai Medical Center, 127 S San Vicente Blvd. AHSP A8308, Los Angeles, CA, 90048, USA. Dmitriy.Sheyn@csmc.edu.
Cedars-Sinai Medical Center · USInstitute of Fundamental Technological Research · PLWest China Hospital of Sichuan University · CN

Funding

Induced pluripotent stem cell therapy for degenerated IVDK01AR071512 · NIAMS · CEDARS-SINAI MEDICAL CENTER · PI SHEYN, DMITRIY · 2018 to 2022
$595k
NIAMS NIH HHS K01 AR071512
6 · The paper itself

Abstract

Cranial bone loss presents a major clinical challenge and new regenerative approaches to address craniofacial reconstruction are in great demand. Induced pluripotent stem cell (iPSC) differentiation is a powerful tool to generate mesenchymal stromal cells (MSCs). Prior research demonstrated the potential of bone marrow-derived MSCs (BM-MSCs) and iPSC-derived mesenchymal progenitor cells via the neural crest (NCC-MPCs) or mesodermal lineages (iMSCs) to be promising cell source for bone regeneration. Overexpression of human recombinant bone morphogenetic protein (BMP)6 efficiently stimulates bone formation. The study aimed to evaluate the potential of iPSC-derived cells via neural crest or mesoderm overexpressing BMP6 and embedded in 3D printable bio-ink to generate viable bone graft alternatives for cranial reconstruction. Cell viability, osteogenic potential of cells, and bio-ink (Ink-Bone or GelXa) combinations were investigated in vitro using bioluminescent imaging. The osteogenic potential of bio-ink-cell constructs were evaluated in osteogenic media or nucleofected with BMP6 using qRT-PCR and in vitro μCT. For in vivo testing, two 2 mm circular defects were created in the frontal and parietal bones of NOD/SCID mice and treated with Ink-Bone, Ink-Bone + BM-MSC-BMP6, Ink-Bone + iMSC-BMP6, Ink-Bone + iNCC-MPC-BMP6, or left untreated. For follow-up, µCT was performed at weeks 0, 4, and 8 weeks. At the time of sacrifice (week 8), histological and immunofluorescent analyses were performed. Both bio-inks supported cell survival and promoted osteogenic differentiation of iNCC-MPCs and BM-MSCs in vitro. At 4 weeks, cell viability of both BM-MSCs and iNCC-MPCs were increased in Ink-Bone compared to GelXA. The combination of Ink-Bone with iNCC-MPC-BMP6 resulted in an increased bone volume in the frontal bone compared to the other groups at 4 weeks post-surgery. At 8 weeks, both iNCC-MPC-BMP6 and iMSC-MSC-BMP6 resulted in an increased bone volume and partial bone bridging between the implant and host bone compared to the other groups. The results of this study show the potential of NCC-MPC-incorporated bio-ink to regenerate frontal cranial defects. Therefore, this bio-ink-cell combination should be further investigated for its therapeutic potential in large animal models with larger cranial defects, allowing for 3D printing of the cell-incorporated material.

Indexed as

Induced Pluripotent Stem CellsAnimalsCell DifferentiationHumansInkMiceMice, Inbred NODMice, SCIDNeural CrestOsteogenesis

Identifiers

PMID36333414
PMCPMC9636385
OpenAlexW4308211108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.